Assembly Biosciences Banks $100M and Unveils First ABI-6250 Data in Dual-Pronged Strategy
25.05.2026 - 12:23:50 | boerse-global.de
When Assembly Biosciences took the stage at the EASL congress in Barcelona on May 27, it did so with a freshly filled coffer. The biotech group closed a $100 million capital raise just a day earlier, then presented the first public clinical data for its lead candidate ABI-6250 — a rare one-two punch of financing and science that signals an aggressive push into liver disease.
A $100M Bet Backed by Heavy Hitters
The underwritten public offering consisted of roughly 3.36 million shares priced at $26.50 each, alongside pre-funded warrants covering up to 415,000 additional shares. Investors also received a 30-day option to purchase up to 566,040 more shares. Net proceeds from the deal, which was led by Guggenheim Securities and UBS Investment Bank, come to just under $100 million after expenses.
The investor syndicate reads like a who’s who of biotech finance: Farallon Capital Management, Commodore Capital, Columbia Threadneedle Investments, and other dedicated healthcare funds all participated. Most notably, Gilead Sciences joined the round — deepening a partnership that already covers herpes, hepatitis B, and hepatitis D programs. That Gilead put its own capital behind the raise underscores the breadth of Assembly’s pipeline, which extends well beyond the HDV-focused data just presented.
The $26.50 offering price represented a modest discount to the prior Friday’s close of $28.34. Assembly’s shares had shed roughly 16% year-to-date, and the RSI hovered near 38 — territory financial technicians often read as mildly oversold. The new funds are intended to bankroll the clinical development of the entire product portfolio.
Should investors sell immediately? Or is it worth buying Assembly Biosciences?
First Glimpse of ABI-6250 in Phase 1a
The EASL presentation marked the first public data release for ABI-6250, an oral entry inhibitor designed to block the NTCP transporter — the receptor the hepatitis D virus uses to enter liver cells. The randomised, blinded Phase 1a trial enrolled healthy volunteers and evaluated single and multiple ascending doses for safety, pharmacokinetics, and pharmacodynamic activity.
Results showed dose-dependent target activation, evidenced by elevated plasma bile acid levels — confirming that the drug was hitting the NTCP transporter as intended. Chronic toxicology studies have been completed, providing the safety package needed for longer dosing in future trials. Assembly plans to move ABI-6250 into Phase 2 for HDV in the fourth quarter of 2026, and into a basket study — or separate Phase 2 trials — for the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) in the first quarter of 2027. The company notes ABI-6250 is currently the only oral entry inhibitor in clinical development for HDV.
Gilead’s Option Looms Mid-2026
The partnership with Gilead extends beyond financing. Assembly has until mid-2026 to decide whether to exercise its option on a US co-development agreement for two herpes simplex candidates, ABI-5366 and ABI-1179. The proposed structure calls for a 40% share of both costs and profits, with Gilead retaining exclusive rights, clinical development responsibility, and commercialisation control. Opting in would hand Assembly a larger slice of potential US revenues — but also tie the company to meaningful late-stage funding commitments.
Assembly Biosciences at a turning point? This analysis reveals what investors need to know now.
Analyst Optimism Remains High
Wall Street continues to see upside. Seven analysts cover the stock with a consensus price target of $42.67, while HC Wainwright & Co. leads the bulls at $50. The three most recent ratings from HC Wainwright and Guggenheim average $47.67 — well above the offering price. Tangible book value stood at $12.50 per share as of March 31, meaning the $100 million raise substantially bolsters that base and extends the cash runway into a second half packed with Phase 2 decisions and the looming Gilead opt-in deadline.
Ad
Assembly Biosciences Stock: New Analysis - 25 May
Fresh Assembly Biosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
